Somatostatin Analogs: How we choose, and why
Octreotide long-acting release (LAR) has been used since the early 1990 ’s to slow tumor growth in well differentiated neuroendocrine tumors (NETs). The original registration for octreotide LAR was for control of hormone-related symptoms, however prolonged progression-free survival (PFS) was shown in the PROMID study, a randomized, double-blind, placebo-controlled tri al in midgut NETs [1]. That study was not powered to evaluate overall survival, and the data were never submitted to regulatory authorities to seek an indication for octreotide LAR as an antineoplastic agent. (Source: Seminars in Oncology)
Source: Seminars in Oncology - August 4, 2017 Category: Cancer & Oncology Authors: Diane Reidy-Lagunes, Nitya Raj, Leonard Saltz Source Type: research
In reply
To the Editor: (Source: Seminars in Oncology)
Source: Seminars in Oncology - August 4, 2017 Category: Cancer & Oncology Authors: Michele Boisdron-Celle, Olivier Capitain, Roger Faroux, Christophe Borg, Jean Philippe Metges, Marie Pierre Galais, Mehdi Kaassis, Jaafar Bennouna, Karine Bouhier-Leporrier, Eric Francois, Isabelle Baumgaertner, V éronique Guerin-Meyer, Oana Cojocarasu, Source Type: research
“Mind the Gap” Revisited
We note with interest the article by Evans et al recently published in Seminars in Oncology [1]. The authors compared access to cancer medicines in New Zealand and Australia and examined the potential foregone population health gains due to differences in the ready availability of anti-cancer pharmaceuticals in each country. However, we are concerned that the authors have used a flawed methodological approach in making such comparisons and failed to address the potential role of access to pharmaceuticals available in many other developed countries, to the fundamental differences in cancer survival between the two countries...
Source: Seminars in Oncology - August 2, 2017 Category: Cancer & Oncology Authors: John R. Zalcberg, Michael Wonder Source Type: research
Angiogenesis Inhibition in the Second-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis
The last two decades have seen intensive efforts devoted to the development of compounds that target angiogenesis for the treatment of metastatic colorectal cancer (mCRC). In this review, we describe supporting evidence and ongoing development of angiogenesis inhibitors in the second-line treatment of mCRC, and summarize relevant randomized trials to help therapeutic decision-making in daily practice. (Source: Seminars in Oncology)
Source: Seminars in Oncology - August 2, 2017 Category: Cancer & Oncology Authors: Ralph Chebib, Loic Verlingue, Nathalie Cozic, Matthieu Faron, Pascal Burtin, Val érie Boige, Antoine Hollebecque, David Malka Source Type: research
"Mind the Gap" Revisted
Dear Sir/Madam, (Source: Seminars in Oncology)
Source: Seminars in Oncology - August 2, 2017 Category: Cancer & Oncology Authors: John Zalcberg Source Type: research
outside front cover
(Source: Seminars in Oncology)
Source: Seminars in Oncology - August 1, 2017 Category: Cancer & Oncology Source Type: research
Masthead
(Source: Seminars in Oncology)
Source: Seminars in Oncology - August 1, 2017 Category: Cancer & Oncology Source Type: research
Editorial Board
(Source: Seminars in Oncology)
Source: Seminars in Oncology - August 1, 2017 Category: Cancer & Oncology Source Type: research
Table of Contents
(Source: Seminars in Oncology)
Source: Seminars in Oncology - August 1, 2017 Category: Cancer & Oncology Source Type: research
Biographies of the authors
Megan Kruse is associate staff in Medical Oncology at Cleveland Clinic. She is a graduate of Case Western Reserve University School of Medicine and completed her Internal Medicine residency at the University of Pittsburgh Medical Center. Her fellowship training in Hematology and Medical Oncology at Cleveland Clinic included a Chief Fellow year during which she was involved in curricular development. She specializes in the treatment of breast cancer and is particularly interested in improving communication strategies between providers and patients. (Source: Seminars in Oncology)
Source: Seminars in Oncology - August 1, 2017 Category: Cancer & Oncology Source Type: research
Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer —A definite conclusion?
This review on the use of anti-angiogenic agents in second-line treatment of metastatic colorectal cancer (mCRC) has carefully examined a large amount of data coming from more than 20 randomized studies with a pertinent analysis method [1]. The second part of the work presents the results of a meta-analysis of published data and provides new insight on this pragmatic question that we all face in our daily clinical practice. (Source: Seminars in Oncology)
Source: Seminars in Oncology - July 29, 2017 Category: Cancer & Oncology Authors: M. Ducreux, P. Österlund, J.P. Pignon Tags: Commentary Source Type: research
Angiogenesis Inhibition in the Second-Line Treatment of Metastatic Colorectal Cancer. A Definite Conclusion?
This review on the use of anti-angiogenic agents in second line treatment of metastatic colorectal cancer (mCRC) has carefully examined a large amount of data coming from more than 20 randomized studies with a pertinent analysis method [1]. The second part of the work presents the results of a meta-analysis of published data and provides new insight on this pragmatic question that we all face in our daily clinical practice. (Source: Seminars in Oncology)
Source: Seminars in Oncology - July 29, 2017 Category: Cancer & Oncology Authors: M. Ducreux, P. Österlund, J.P. Pignon Tags: Commentary Source Type: research
Long-acting Somatostatin Analogues in the Treatment of Unresectable/Metastatic Neuroendocrine Tumors
Neuroendocrine tumors (NETs) are a relatively rare and heterogeneous group of neoplasms with an annual incidence of ~35 cases per 100,000 people in the U.S. The updated World Health Organization (WHO) classification system of gastroenteropancreatic (GEP-) NETs categorizes these tumors according to site of origin, clinical syndrome, and degree of differentiation. Well-differentiated NETs arising from the gastrointestinal tract or lungs (formerly known as carcinoid tumors) are often indolent and slowly growing. (Source: Seminars in Oncology)
Source: Seminars in Oncology - July 25, 2017 Category: Cancer & Oncology Authors: Thomas Enzler, Tito Fojo Source Type: research
Nivolumab and Pembrolizumab: Monoclonal Antibodies Against Programmed Cell Death-1 (PD-1) that are Interchangeable
Nivolumab (Opdivo ®, Bristol Meyer Squibb) and pembrolizumab (Keytruda®, Merck) are the first two FDA approved monoclonal antibodies targeting programmed death-1 (PD-1). Nivolumab and pembrolizumab work by interfering with the interaction between (PD-1) and programmed death-ligand-1 (PD-L1), whose unimpeded interac tion downregulates T-cells allowing cancer cells to evade immune surveillance.1-3 [Figure 1] These drugs have earned a series of US Food and Drug Administration US FDA) approvals for melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), urothelial cancer, classica l Hodgkin...
Source: Seminars in Oncology - July 13, 2017 Category: Cancer & Oncology Authors: Vinay Prasad, Victoria Kaestner Source Type: research
